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Accepted 16 April 2012AbstractObjective: To investigate the various genotypes of human papillomavirus (HPV) in Taiwanese women patients with abnormal cervical cytology
and analyze the associations between HPV types, cervical preinvasive lesions, and the medical characteristics of these patients.
Materials and Methods: We performed HPV genotyping GeneChip procedures and colposcopies for 784 women with abnormal Papanicolaou
smears. The characteristics of the patients and the status of the HPV infection were correlated.
Results: A total of 706 (90.1%) of the 784 women were positive for HPV infection, including 641 patients with high-risk HPV (HR-HPV).
Among the patients with high-grade squamous intraepithelial lesions (HSILs), the average age of the 273 patients with other HR-HPV types
(48.6  13.8 years) was significantly older than the 222 patients infected with HPV 16/18 (39.8  11.8 years) ( p < 0.001). The proportion of
patients with HSILs who were older than 40 years and infected with other HR-HPV types (76.6%) was also significantly higher than those with
HPV 16/18 (20.3%) ( p < 0.001).
Conclusion: Women older than 40 years and having abnormal Pap smears and HR-HPV infections other than type 16/18 should be managed
carefully because of the risk for HSILs.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Cervical cancer is the most prevalent gynecological ma-
lignancy and results in considerable morbidity and mortality.
The prevalence of cervical cancer has been significantly
reduced globally because Pap smear screening programs are
conducted in most countries; however, it continues to be a
major health concern among women in less developed* Corresponding author. Department of Obstetrics and Gynecology, College
of Medicine, National Taiwan University, Number 8, Chung-Shan South Road,
Taipei 100, Taiwan.
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1028-4559/$ - see front matter Copyright  2013, Taiwan Association of Obstetri
http://dx.doi.org/10.1016/j.tjog.2013.04.012countries [1]. zur Hausen first proposed the association be-
tween the human papillomavirus (HPV) and cervical cancer,
and the role of HPV in the carcinogenesis of cervical cancer
has now been confirmed [2]. Patients with persistent infections
of the high-risk HPV (HR-HPV) types have an increased risk
of developing cervical carcinoma. HPV 16 and 18 are the two
leading genotypes that are detected in women with cervical
neoplasm worldwide [3,4]. The addition of the HPV test to
Pap smear testing has provided a more sensitive and cost-
effective way for the early detection of cervical lesions,
especially in patients with atypical squamous cells of unde-
termined significance (ASCUS) [5,6]. At present, it has been
suggested that a combination of the HPV test and Pap smearcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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minimize unnecessary management of these lesions [7,8]. This
study was conducted to investigate the HPV genotypes in
Taiwanese women patients with abnormal cervical cytology
results and analyze the associations between HPV types, cer-
vical preinvasive lesions, and the characteristics of these
patients.
Materials and MethodsPatient recruitmentFrom January 1, 2000 to December 31, 2007, consecutive
patients with cytological abnormalities presenting to our
institution were recruited for this investigation. The research
protocol was approved by the Ethics Committee of the Na-
tional Taiwan University Hospital, and written informed
consent forms were obtained from each patient. The medical
characteristics of these patients were retrieved from the
medical records. Results of the Pap smear tests were reviewed
according to the terminologies specified in the 2001 Bethesda
System [9]. The study included patients with cytological ab-
normalities, including ASCUS, atypical squamous cells not
excluding high-grade squamous intraepithelial lesions
(HSILs), atypical glandular cells not otherwise specified,
atypical glandular cells favoring neoplasm, low-grade squa-
mous intraepithelial lesions (LSILs), HSILs, and malignant
diseases. The intervals between performing the Pap smears,
HPV DNA testing, and colposcopic examinations were less
than 3 months. Cervical biopsies and/or endocervical curet-
tages were performed if indicated at the colposcopic clinics of
our hospital. The indications for a loop electrosurgical exci-
sion procedure (LEEP) or conization consisted of a
colposcope-directed cervical biopsy or a endocervical curet-
tage showing cervical intraepithelial neoplasia (CIN) 2/3 or
adenocarcinoma in situ, cytological HSIL with an unsatisfac-
tory colposcopy, and discrepancies between the results of
cytological analysis and cervical biopsy. The intervals between
colposcope-directed biopsies and LEEP or conization were
less than 1 month. We enrolled those patients who underwent
hysterectomies for the primary treatment of CIN 2/3, adeno-
carcinoma in situ, or other gynecologic benign lesions such as
uterine fibroids or ovarian tumors, or patients who had had a
hysterectomy within 12 weeks after conization for further
analysis. Patients who had a cone diagnosis of cervical cancer,
refused to receive HPV DNA testing, underwent a hysterec-
tomy more than 12 weeks after primary diagnosis or coniza-
tion, or refused to participate in the study were excluded.
Patients who had ever received an HPV vaccine and patients
with a past history of cervical cancer or precancerous lesions
were also excluded.HPV detection and genotyping by GeneChipWe performed HPV tests using the cervical swabs of the
recruited patients before colposcopies, cervical biopsies, or
conizations were considered. DNA extraction and polymerasechain reaction (PCR) were then performed from the cells ac-
quired from the cervical swab as described previously [10]. In
brief, short PCR fragment 1/general primer 6 þ PCR was
performed for 40 cycles. The resultant PCR products were
hybridized with a commercial HPV genotyping array mem-
brane (King Car Food Industrial Co., Ltd., I-lan, Taiwan) in a
single reaction. HPV Blotting contains 38 types of HPV (6, 11,
16, 18, 26, 31, 32, 33, 35, 37, 39, 42, 43, 44, 45, 51, 52, 53, 54,
55, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71 [CP8061], 72, 74,
81 [CP8304], 82 [MM4], 83 [MM7], 84 [MM8], and L1AE5)
oligonucleotide probes (20e30 mer) on a nylon membrane.
The hybridization and detection procedures were described
previously [11].
Direct sequence analysis was performed on the HPV-
positive products periodically. The HPV genotypes MM4,
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 82 were
regarded as HR-HPV types; 26 and 53 were regarded as
probable HR-HPV types; and the other types were regarded as
low-risk HPV (LR-HPV) types [12]. When HPV-negative re-
sults were noted in the first round, a glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) PCR was performed to
validate the HPV negativity. If the GAPDH PCR was also
negative, another PCR for GAPDH and HPV infection was
performed. In cases of GAPDH positivity and a negative
repeat of the HPV Blot, the final result was designated as HPV
negative.
After primary treatment with LEEP, conization, or hyster-
ectomy, the patients underwent regular Pap smear tests and/or
colposcopic examinations at 3- to 6-month intervals in the first
3 years, and then annually for follow-up.Statistical analysisThe data were computerized and analyzed using SPSS for
Windows, version 10.0.7C, SPSS Inc., (Chicago, IL, USA).
Comparisons between unpaired groups were made using Stu-
dent t test, ManneWhitney U test, one-way analysis of vari-
ance (ANOVA), c2 test, and KruskaleWallis test.
Results
A total of 784 women matched the study criteria and were
recruited for this study (Fig. 1). The age of these patients
ranged from 20 to 87 years, with a mean age of 45.2 years, and
199 (25.4%) were menopausal women. Of the 784, 594
(75.8%) women received LEEP or conization, and 52 (6.6%)
underwent a hysterectomy as the primary treatment. A total of
646 women had a histological diagnosis, and the other 138
women did not have a cervical biopsy because of negative
colposcopic findings. Among the patients with a histological
diagnosis of preinvasive cervical lesions, we noted positive
section margins on the LEEP/conization specimens in 59 pa-
tients. A total of 21 patients subsequently underwent hyster-
ectomies, of which 17 (80.9%) had residual CIN lesions in
their hysterectomy specimens. Among the other patients with
negative section margins on the LEEP/conization specimens,
34 underwent a hysterectomy for other indications and out of
Fig. 1. Flowchart of the current investigation. The final cytopathological diagnoses, treatments, outcomes, and HPV genotyping are summarized.
ASCUS ¼ atypical squamous cells of undetermined significance; CIN ¼ cervical intraepithelial neoplasia; HPV ¼ human papillomavirus; HR ¼ high risk;
HSIL ¼ high-grade squamous intraepithelial lesion; LEEP ¼ loop electrosurgical excision procedure; LR ¼ low risk; LSIL ¼ low-grade squamous intraepithelial
lesion.
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final diagnosis was based on the worst of both the cytological
and histological findings. Cervical cancer was diagnosed in 33
patients (4.2%), HSIL in 577 patients (73.6%), LSIL in 105
patients (13.4%), and ASCUS in 69 patients (8.8%).
The HPV infection was detected by a genotyping chip in 706
(90.1%) of the 784 women with abnormal Pap smears. Of them,
641 (90.8%) were infected with HR-HPV and 65 (9.2%) were
infectedwithLR-HPV.Therewere159womenwhowere infected
with more than one HPV type. Of the 641 women infected with
HR-HPV, 276 (43.1%) of themwere infectedwithHPV16 and/or
18, and 365 (56.9%) of them were infected with the other HR-
HPV types. The distribution of HPV types for all the 784
women is summarized in Table 1. The percentages of HR-HPV
infection increased from ASCUS to invasive cancer (Fig. 2,
p< 0.001,ManneWhitneyU test). When focusing on individual
HPVgenotypes, the percentages ofHPV16 ( p< 0.001) andHPV
18 (p¼ 0.039) infection significantly increased from ASCUS to
invasive cancer; HPV 31 ( p ¼ 0.071) and HPV 58 ( p ¼ 0.067)
infections showed marginal increase, but HPV 33 ( p ¼ 0.311),
HPV 35 ( p ¼ 0.650), and HPV 52 ( p ¼ 0.159) were not signif-
icantly different (ManneWhitney U test).
We also analyzed the relationships among age, cervical
preinvasive lesions, and HPV infection. In 105 patients withLSIL, the mean ages did not differ among the women with
HPV 16/18 infections (45.6  15.6 years old), the other HR-
HPV types of infection (42.2  10.6), the LR-HPV type in-
fections, and those without HPV infection (41.7  13.4)
( p ¼ 0.565, one-way ANOVA test). In 577 patients with
HSIL, 222 patients were infected with HPV 16/18, 273 pa-
tients with other HR-HPV types, and 82 patients with either
LR types or were without HPV infection (Table 2). In patients
with HSIL, the average age of the 273 patients with other HR-
HPV types (48.6  13.8 years) was significantly older than the
222 patients infected with HPV 16/18 (39.8  11.8 years)
( p < 0.001, one-way ANOVA test). The proportion of the
HSIL patients older than 40 years and infected with other HR-
HPV types (76.6%) was also significantly higher than that of
the HPV 16/18 patients (20.3%) ( p < 0.001, KruskaleWallis
test). In addition, a higher proportion of the HSIL patients
infected with other types of HR-HPV were in menopause as
compared to those infected with HPV 16/18 ( p < 0.001,
ManneWhitney U test).
Discussion
The HR-HPV infection is involved in the carcinogenesis of
the uterine cervix. In our study, HR-HPV was detected in all of
Table 1
Distribution of HPV genotypes in all patients.
HPV types Total
(n)
% ASCUS
(n)
% LSIL
(n)
% HSIL
(n)
% CC
(n)
%
784 69 105 577 33
MM4 3 0.4 0 0.0 1 1.0 2 0.4 0 0
16 217 27.7 11 15.9 16 15.2 174 30.2 16 48.5
18 64 8.2 3 4.4 3 2.9 52 9.0 6 18.2
26 3 0.4 1 1.5 2 1.9 2 0.4 0 0
31 32 4.1 0 0.0 2 1.9 30 5.2 0 0
33 48 6.1 4 5.8 3 2.9 36 6.2 5 15.2
35 20 2.6 2 2.9 4 3.8 15 2.6 1 3.0
39 23 2.9 4 5.8 4 3.8 15 2.6 0 0
45 11 1.4 0 0.0 2 1.9 9 1.6 0 0
51 23 2.9 2 2.9 6 2.9 36 6.2 0 0
52 103 13.1 3 4.4 15 14.3 81 14.0 4 12.1
53 34 4.3 0 0.0 15 14.3 19 3.3 1 3.0
56 19 2.4 1 1.5 8 7.6 10 1.7 0 0
58 94 12.0 2 2.9 8 7.6 78 13.5 4 12.1
59 17 2.2 2 2.9 3 2.9 10 1.7 0 0
68 16 2.0 0 0.0 1 1.0 8 1.4 0 0
82 10 1.3 0 0.0 0 0.0 3 0.5 0 0
LR types 65 8.3 7 10.1 18 17.1 40 6.9 0 0
Negative 78 9.9 27 39.1 10 9.5 41 7.1 0 0
Percentages add up to more than 100 due to some patients being infected with multiple HPV types. ASCUS ¼ atypical squamous cells of undetermined sig-
nificance; CC ¼ cervical cancer; HPV ¼ human papillomavirus; HSIL ¼ high-grade squamous intraepithelial lesion; LR ¼ low risk; LSIL ¼ low-grade squamous
intraepithelial lesion; n ¼ patient number.
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HSIL, 72% of the patients with LSIL, and 51% of the patients
with ASCUS. The proportions of HR-HPV infection increased
from ASCUS to more aggressive lesions, especially in women
infected with HPV 16, 18, 52, and 58 genotypes. The
increased proportion of the HR type in the HSILs and invasive
cancers may imply that these genotypes had the ability to
evade the immune protection of the host and cause oncogenic
changes in the cervix. The prevalent HPV genotypes in our
study were compatible with the previous studies in which HPV
52 and 58 were the most prevalent types of cervical pre-
invasive and invasive lesions in addition to HPV 16 and 18
[13,14] in Asia.
The HSIL in relation to HR-HPV, other than type 16/18,
predominantly occurred in woman older than 40 years. These
women may have recovered from previous HPV 16/18-Fig. 2. Proportion of HPV types in all patients. The proportion of HR-HPV
infection increased as the cervical lesions progressed from ASCUS to
aggressive lesions ( p < 0.001, ManneWhitney U test). ASCUS ¼ atypical
squamous cells of undetermined significance; HPV ¼ human papillomavirus;
HR ¼ high risk; HSIL ¼ high-grade squamous intraepithelial lesion;
LR ¼ low risk; LSIL ¼ low-grade squamous intraepithelial lesion.associated cervical lesions at a younger age, before they
received the screening in our study. Consequently, we
excluded women with a previous history of cervical pre-
invasive lesions or cervical cancer from enrolling in this
study to reduce the interference from this factor. In the study
of HPV genotypes in 1086 Taiwanese women with CIN 2/3
conducted by Chao et al, HPV 16 and 18 comprised 21.3%,
whereas HPV 52, 58, and 33 represented 55.5% in women
older than 50 years. In women under the age of 50, HPV 16
and 18 comprised 32.1%, whereas HPV 52, 58, and 33 rep-
resented 47.9%. These results were consistent with our find-
ings [15]. The current HPV vaccine for children/young women
aged between 9 and 26 years has been proven to prevent HPV
16- and 18-related HSIL effectively [16,17]. Women with
HSIL derived from other HR-HPV types will be the more
important problem in the era of HPV vaccination worldwide.
The addition of the HPV test to the Pap smear is currently
suggested in the screening of cervical cancer [7], and the HPV
test is recommended as a triage test for women with ASCUS
[5,18]. However, controversy exists over the utility of the HPV
test for general cervical cancer screening [19]. Type-specific
HPV screening should be the next step for HPV testing
instead of the nontyping Hybrid Capture assays [20]. Our
study could assist in the clinical utilization of HPV genotyping
testing in patients with abnormal cervical cytological findings.
Women older than 40 years, who have abnormal Pap smear
results and an HR-HPV infection other than type 16/18, should
be carefully managed to avoid the risk of developing cervical
HSIL.
In conclusion, this investigation provides useful informa-
tion about the association of HPV genotypes and cervical
preinvasive lesions. In the era of an HPV vaccination against
Table 2
Relationship between age and HPV genotypes in the 577 patients with HSIL.
Patient numbers HPV 16/18 Other HR-HPV
types
LR-HPV or
HPV negative
p
222 273 82
Age (y/o) 39.8  11.8 48.6  13.8 47.8  13.4 <0.001
Age  40 (y/o)
Yes
No
45 (20.3%)
177 (79.7%)
209 (76.6%)
64 (23.4%)
59 (72.0%)
23 (28.0%)
<0.001
Menopause
Yes
No
33 (14.9%)
189 (85.1%)
91 (33.3%)
182 (66.7%)
23 (28.0%)
59 (72.0%)
<0.001
HPV ¼ human papillomavirus; HR ¼ high risk; HSIL ¼ high-grade squamous
intraepithelial lesion; LR ¼ low risk.
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important role in clinical practice. A combination of Pap
smear testing and HPV genotyping will be the trend of
screening in the future.
References
[1] Bureau of Health Promotion, Department of Health, R.O.C. (Taiwan).
Cancer registration system annual report. https://cris.bhp.doh.gov.tw/
pagepub/home.aspx.
[2] zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer 2002;2:342e50.
[3] Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al.
Prevalence of human papillomavirus in cervical cancer: a worldwide
perspective. International biological study on cervical cancer (IBSCC)
Study Group. J Natl Cancer Inst 1995;87:796e802.
[4] Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M,
Wacholder S, et al. HPV DNA testing in cervical cancer screening: re-
sults from women in a high-risk province of Costa Rica. JAMA
2000;283:87e93.
[5] ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial
on the management of cytology interpretations of atypical squamous
cells of undetermined significance. Am J Obstet Gynecol
2003;188:1383e92.
[6] Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER,
Schiffman M, et al. Cost-effectiveness analysis based on the atypical
squamous cells of undetermined significance/low-grade squamousintraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst
2006;98:92e100.
[7] Wright Jr TC, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S,
et al. Interim guidance for the use of human papillomavirus DNA testing
as an adjunct to cervical cytology for screening. Obstet Gynecol
2004;103:304e9.
[8] Wright Jr TC. Cervical cancer screening in the 21st century: is it time to
retire the PAP smear? Clin Obstet Gynecol 2007;50:313e23.
[9] Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M,
et al. The 2001 Bethesda System: terminology for reporting results of
cervical cytology. JAMA 2002;287:2114e9.
[10] Huang SL, Chao A, Hsueh S, Chao FY, Huang CC, Yang JE, et al.
Comparison between the hybrid capture II test and an SPF1/GP6þ PCR-
based assay for detection of human papillomavirus DNA in cervical swab
samples. J Clin Microbiol 2006;44:1733e9.
[11] Huang HJ, Huang SL, Lin CY, Lin RW, Chao FY, Chen MY, et al. Human
papillomavirus genotyping by a polymerase chain reaction-based
GeneChip method in cervical carcinoma treated with neoadjuvant
chemotherapy plus radical surgery. Int J Gynecol Cancer 2004;14:639e49.
[12] Mun˜oz N. Human papillomavirus and cancer: the epidemiological evi-
dence. J Clin Virol 2000;19:1e5.
[13] Liaw KL, Hsing AW, Schiffman MH, You SL, Zhang T, Burk R, et al.
Human papillomavirus types 52 and 58 are prevalent in cervical cancer
from Chinese women. Int J Cancer 1997;73:775e6.
[14] Chen CA, Liu CY, Chou HH, Chou CY, Ho CM, Twu NF, et al. The
distribution and differential risks of human papillomavirus genotypes in
cervical preinvasive lesions: A Taiwan Cooperative Oncologic Group
Study. Int J Gynecol Cancer 2006;16:1801e8.
[15] Chao A, Jao MS, Huang CC, Huang HJ, Cheng HH, Yang JE, et al.
Human papillomavirus genotype in cervical intraepithelial neoplasia
grades 2 and 3 of Taiwanese women. Int J Cancer 2011;128:653e9.
[16] Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB,
et al. A controlled trial of a human papillomavirus type 16 vaccine. N
Engl J Med 2002;347:1645e51.
[17] FUTURE II Study Group. Quadrivalent vaccine against human papillo-
mavirus to prevent high-grade cervical lesions. N Engl J Med
2007;356:1915e27.
[18] Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S,
Hildesheim A, et al. A study of the impact of adding HPV types to
cervical cancer screening and triage tests. J Natl Cancer Inst
2005;97:147e50.
[19] Irwin K, Montan˜o D, Kasprzyk D, Carlin L, Freeman C, Barnes R, et al.
Cervical cancer screening, abnormal cytology management, and coun-
seling practices in the United States. Obstet Gynecol 2006;108:397e409.
[20] Schiffman M. Integration of human papillomavirus vaccination,
cytology, and human papillomavirus testing. Cancer 2007;111:145e53.
